Old Mission Investment Co LLC Takes $502,000 Position in Amgen Inc. $AMGN

Old Mission Investment Co LLC bought a new position in Amgen Inc. (NASDAQ:AMGN) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,385 shares of the medical research company’s stock, valued at approximately $502,000.

A number of other hedge funds have also made changes to their positions in the company. Anfield Capital Management LLC increased its holdings in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares in the last quarter. Dogwood Wealth Management LLC boosted its holdings in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares in the last quarter. Tower View Wealth Management LLC boosted its holdings in shares of Amgen by 331.6% in the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after acquiring an additional 63 shares in the last quarter. Manning & Napier Advisors LLC grew its position in Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares during the last quarter. Finally, Evergreen Advisors LLC acquired a new stake in Amgen during the 1st quarter valued at $37,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Repatha data could expand its addressable market. Amgen reported that Repatha reduced all-cause mortality by 20% in a prespecified analysis of the Phase 3 VESALIUS-CV trial, which studied more than 12,000 high-risk adults who had not previously experienced a heart attack or stroke. Earlier use could support broader adoption of the cardiovascular drug. Amgen Repatha VESALIUS-CV article
• Positive Sentiment: MariTide retains a potential convenience advantage in obesity treatment. Amgen’s investigational therapy could require less-frequent dosing than competing treatments from Eli Lilly and Novo Nordisk. That feature may help differentiate MariTide if its clinical and regulatory profile supports approval, although competition in the market remains intense. Amgen MariTide obesity article
• Neutral Sentiment: Shares had recently approached a 52-week high. Recent strength followed better-than-expected quarterly earnings and raised 2026 guidance, but the stock’s elevated valuation and gains left it more vulnerable to profit-taking when adverse regulatory news emerged. Amgen stock and 2026 guidance article
• Negative Sentiment: U.K. action against Tavneos intensified regulatory risk. The U.K. regulator suspended Tavneos for new patients and indicated a path toward revoking its authorization in March 2027, saying the drug’s benefit-risk balance was no longer favorable and that its pivotal efficacy study could not be relied upon. This compounds the FDA’s April proposal to withdraw U.S. approval over effectiveness, application-disclosure and liver-safety concerns, raising the possibility of broader loss of value for the drug. Amgen Tavneos regulatory pressure article
• Negative Sentiment: Insider selling added a modest sentiment headwind. Reported insider transactions showed seven sales and no purchases over the past six months, though these trades are less significant than the Tavneos developments. Amgen trading disclosures article

Insider Buying and Selling

In other Amgen news, SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. This represents a 28.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at $2,642,098.28. This represents a 23.80% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 6,222 shares of company stock worth $2,540,926. Company insiders own 0.85% of the company’s stock.

Amgen Trading Down 1.6%

AMGN stock opened at $437.23 on Friday. The stock has a market cap of $236.38 billion, a price-to-earnings ratio of 27.17, a price-to-earnings-growth ratio of 3.20 and a beta of 0.43. The company has a fifty day moving average price of $397.39 and a two-hundred day moving average price of $367.15. Amgen Inc. has a one year low of $269.77 and a one year high of $447.03. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts anticipate that Amgen Inc. will post 22.97 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be paid a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.3%. Amgen’s payout ratio is 62.65%.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Scotiabank lifted their price objective on Amgen from $385.00 to $450.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Truist Financial raised their target price on Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Piper Sandler lifted their price target on Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Canaccord Genuity Group upped their price target on shares of Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Finally, TD Cowen increased their price objective on shares of Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $381.68.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.